ASCO GU 2017: A Therapeutic Update on Emerging Combination Regimens to Improve Outcomes for Patients with Advanced Renal Cell Carcinoma

http://academiccme.com/wp-content/uploads/2017/05/iStock-518225933-wpcf_400x400.jpg

Course Information

Therapautic Area: Oncology
Format(s): Post Conference Review and Analysis
Credit(s): 1.0 AMA PRA Category 1 Credit(s)™
Activity Dates: May 24, 2017 - May 23, 2018

 

Program Overview

This CME program will highlight recent therapeutic updates on emerging combination regimens to improve outcomes for patients with advanced renal cell carcinoma presented at the 2017 Genitourinary Cancers Symposium from February 16-18, 2017 in Orlando, Florida. Two expert faculty will review pathogenesis and the role of multi-targeted kinase inhibitors for the treatment of advanced renal cell carcinoma. Clinical trial data of emerging combination therapy options for the treatment of advanced renal cell carcinoma will be analyzed. Upon completing this activity, physicians will gain further knowledge and understanding on ways to improve outcomes for patients with advanced renal cell carcinoma.

Target Audience

Oncologists, primary care physicians, and other healthcare clinicians responsible for the care of patients with renal cell carcinoma.

Learning Objectives

1. Review pathogenesis and the role of multi-targeted kinase inhibitors for the treatment of advanced renal cell carcinoma.
2. Analyze clinical trial data of emerging combination therapy options for the treatment of advanced renal cell carcinoma presented at ASCO GU 2017.

Faculty

Michaelson,-Dror_257x320M. Dror Michaelson, MD
Associate Professor of Medicine
Massachusetts General Hospital
Clinical Director
Genitourinary Cancer Center
Boston, Massachusetts

 

amm9052Ana M. Molina, MD
Assistant Professor of Medicine
Weil Cornell Medical College
New York, New York

 

 

 

Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity.

 

Faculty Relationship Identified With:
Marc Dror Michaelson, MD Consultant/Advisor: Exelixis, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.
Ana M. Molina, MD Nothing to disclose.

 

Planners, Managers, Reviewers

Timothy Hayes, MD, PhD; Emma Gilmartin; and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

AcademicCME designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Financial Support

This activity has been supported by an independent educational grant from Eisai Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Eisai Inc. do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Physicians who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME Certificate.
  6. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.

CME Inquiries/Special Needs

For all CME inquiries or special needs, please contact admin@academiccme.com.
BUTTON

 


Provided by AcademicCME.

unnamed